Indeed the use of intratumoral injections of IL-33 promotes antitumor activity of ILC2s either through IL-5 and GM-CSF, which control tumor growth, through the recruitment of eosinophils or through the production of CXCR2 ligands with lytic activity on CXCR2+ tumor cells [126]. Here, IL33 is linked to neoplasm.